AVBP · ArriVent BioPharma Inc
United States · RS rating 9 · As of 2026-11-03
| Price | 13.02 USD |
|---|---|
| 1-day change | -2.5% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 3 / 7 / 31 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 6 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -9.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +62.5% |
| Market cap (USD) | $1.4B |